Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695095 · ClinicalTrials.gov registry record
Acute Liver Injury in Patients on Dapagliflozin
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 424,091
- Enrollment target
NCT02695095 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 424,091 participants.
The verdict
NCT02695095 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 424,091 participants
- Enrollment target
Study Summary
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424,091 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2020-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695095
The ClinicalTrials.gov registry entry for NCT02695095 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 424,091 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02695095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02695095 about?
NCT02695095 is a clinical study titled "Acute Liver Injury in Patients on Dapagliflozin". To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (S...
What is the current status of trial NCT02695095?
This trial is currently completed. The enrollment target is 424,091 participants. The study started on 2017-01-01. Estimated completion is 2020-11-30.
Who is sponsoring clinical trial NCT02695095?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.